Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study (Q36023494)

11 August 2017

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study (English)

1 reference

11 August 2017

1 reference

1 reference

8

Takao Koike

1 reference

11 August 2017

4

Hisashi Yamanaka

1 reference

11 August 2017

Yoshiya Tanaka

1

1 reference

11 August 2017

Masayoshi Harigai

2

1 reference

11 August 2017

Tsutomu Takeuchi

3

1 reference

11 August 2017

Naoki Ishiguro

5

1 reference

11 August 2017

Kazuhiko Yamamoto

6

1 reference

11 August 2017

Nobuyuki Miyasaka

7

1 reference

11 August 2017

Minoru Kanazawa

9

1 reference

11 August 2017

Takuya Oba

10

1 reference

11 August 2017

Toru Yoshinari

11

1 reference

11 August 2017

Daniel Baker

12

1 reference

11 August 2017

GO-FORTH Study Group

13

1 reference

11 August 2017

language of work or name

English

0 references

publication date

25 November 2011

1 reference

Annals of the Rheumatic Diseases

11 August 2017

1 reference

11 August 2017

71

1 reference

11 August 2017

6

1 reference

11 August 2017

817-824

1 reference

Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Molecular mechanisms of inflammatory bone damage: emerging targets for therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

New therapies for treatment of rheumatoid arthritis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Guidelines for the management of rheumatoid arthritis: 2002 Update

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3372319

Measurement of patient outcome in arthritis

21 October 2018

1 reference

12 December 2020

Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis

1 reference

12 December 2020

Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor

1 reference

12 December 2020

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2011.200317

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

22121129

1 reference